entertainment -WSS

entertainment

author：leisure time 2025-10-02 00:29:33 - browse：934

Travere Therapeutics said Thursday that a study meant to confirm the benefit of its newly approved drug for a rare kidney disorder narrowly failed.

In the trial, 404 patients with the disorder, IgA nephropathy, were randomized to receive either Travere’s daily pill, Filspari, or irbesartan, a decades-old blood pressure drug often used to help manage the disease. Early data had showed the drug cut protein levels in the urine, a biomarker of kidney function, by half after nine months. That convinced regulators to give Filspari accelerated approval in February, pending full results using a more direct measure of kidney function.

The new data, after 24 months, showed that patients who received Filspari declined less quickly than those in the control group. But the results just missed statistical significance, with a P value of 0.058.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Plastic surgeons increase patient psychiatric screenings

Wikipedia

entertainment

WSS

Scientists unlock the key to scar

CVS Caremark has created a new ploy: the drug ‘rebate credit’

SCOTUS questions limit to govt efforts to fight misinformation

Readout Newsletter: Bluebird, CVS, Contineum

Plastic surgeons increase patient psychiatric screenings

Virtual Event: March of the Biosimilars

Wikipedia

entertainment

leisure time

Anesthesiologist group: stop taking Ozempic before surgery

Medical device lobby: We're tired of waiting on Medicare coverage

How one medical school became remarkably diverse

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

As demand for Covid shots wanes, Moderna seeks its next success

Intermittent fasting comes with a heart risk? Not so fast

Affirmative action in medical school literally saved lives

Positive childhood experiences can help future health

State Dept. review finds Biden bears some blame for Afghanistan failures

RSV vaccines may be linked to small increased risk of developing GBS

hotspot

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

How to address the problem of discarded donor organs

Neuroscience’s long legacy of racism

Kristina Burow of ARCH Venture Partners shares her next big bets STAT

Methadone treatment changes are coming. Do they go far enough?

U.K. researchers warn about biases in medical devices, algorithms

Wikipedia

entertainment

hotspot

hotspot